Thursday, 16 Aug 2018

You are here

Methotrexate Update

I was delighted to see that investigators presenting work at EULAR 2018 haven’t lost interest in our old friend methotrexate, with a number of abstracts examining issues of safety, dose and route of administration.

Low incidence of methotrexate induced liver abnormalities

Most rheumatologists are very comfortable using methotrexate, but many of our patients have concerns about side effects – especially where liver toxicity is concerned. Research presented by a group from Reading, UK (Abstract SAT0215) should go a long way to help us to reassure them.  The group monitored liver function tests in 1964 rheumatology patients over the course of 13 months. The patient cohort included a mix of patients with RA, PsA, and AS) of whom 775 were taking one concomitant DMARD, 82 were on triple therapy and 396 on a biologic alongside their methotrexate. 

Whereas 2.4% of patients developed an elevated ALT (35-100U/l), only 0.51% (10 patients) developed an ALT >100 U/l. Abnormalities were persistent in 8 of these patients but only resulted in one patient in the cohort discontinuing their methotrexate. Although the reported incidence of ALT abnormalities is a bit lower than that in the published literature (some data on doses of methotrexate used in the cohort would also have been useful) this is good news and echoes  the feeling amongst most rheumatologists that this drug is mostly safe where the liver is concerned The authors also suggest that based on this data, that the current BSR guidelines (which suggest monitoring each 3 months on patients on stable doses of methotrexate) are appropriate.

SC safer than Oral Methotrexate

Most rheumatologists are increasingly comfortable with the use of injectable methotrexate. It certainly appears to be better absorbed and more effective than oral methotrexate a group of researchers from the UK propose that it may be safer too (Abstract SAT0235). Using an online safety monitoring tool, FBC and LFT results were monitored from 8394 patients since 

Whereas the mean dose of MTX used in those on sc dosing was higher (21mg vs 17mg, range 5-40mg) the difference in incidence of LFT abnormalities (ALT > 80 U/l) between the two groups was not statistically significant. Patients on injectable methotrexate however (151/949) were less likely to develop neutropenia than those on oral methotrexate (491/2093) (p <0.00001 sc vs oral). Whereas the liver toxicity data is a little underwhelming, sc methotrexate may well be safer where neutropenias are concerned.

The online monitoring tool used in the study, TA Monitor, was developed by a rheumatologist (http://www.therapyaudit.com/tamonitor/) and allows web based monitoring of adverse events to medications like methotrexate. Another thing that caught my eye in that study as the dose range (up to 40mg) of Methotrexate used.

50mg of sc Methotrexate appears well tolerated

A group of Italian and US researchers have been evaluating the tolerability and safety of higher does of sc Methotrexate in RA (Abstract SAT0228). Their study protocol was an open labelled pilot study of 12 weeks duration, where 9 patients with RA were treated initially with a dose of 50mg of sc methotrexate for 4 weeks, followed by 25mg weekly for 4 weeks and the 15mg weekly for 4 weeks. Overall these higher doses were well tolerated with only AE’s occurring in 4 patients, none of which were severe. One patient developed an ALT (<2 ULN) which resolved spontaneously (the same patient also developed vertigo and subsequently withdrew). One patient developed a UTI, another short lived low back pain which resolved, and one patient developed fatigue. 

Although the numbers are small and study duration short, it will be interesting to see if this regimen proves more effective than traditionally used methotrexate doses in RA.

Add new comment

More Like This

Hydroxychloroquine Being Over-Dosed with New Guidelines?

Hydroxychloroquine retinopathy prevention guidelines have revised from ideal body weight-based dosing to actual body weight-based dosing; the question remains whether these have been adopted in clinical practice. A database of nearly 21,000 new HCQ users from a UK general population database studied HCQ dosing and use between 2007 and 2016. Specifically they examined whether users were subjected to excess HCQ dosing per ophthalmology guidelines (defined by exceeding 6.5 mg/kg of IBW and 5.0 mg/kg of ABW).

NSAID Use Around Conception Increases Miscarriage Risk

A study from the American Journal of Obstetrics & Gynecology analyzed pregnant women from the Kaiser Permanente healthcare system and compared newly pregnant women who took non-steroidal anti-inflammatory drugs or acetaminophen or neither showed that using NSAIDs around conception carried a more than four-fold higher risk of early miscarriage. (Citation source: http://bit.ly/2tqNWN6)

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

Cancer Therapies Inducing Immune-Related Adverse Events (irAEs)

Recent shifts in the cancer treatment paradigm towards immune therapies has led to wide implementation of the novel immune check point inhibitors (ICI) in the treatment of multiple types of advanced cancer.

While being quite effective in oncology, these checkpoint inhibitors have led to the emergence of a quite unique spectrum of rheumatologic conditions presented under the umbrella of immune-related adverse events (irAEs).

Tobacco Associated Deaths in the USA

JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall  mortality risk, and a much highers cancer mortality risk compared to nonsmokers.

The National Longitudinal Mortality Study collected baseline survey data from 1985 through 2011 and included 357,420 participants reporting on their use of cigar, pipes, or cigarettes.